Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been given an average rating of “Moderate Buy” by the seven brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $15.3333.

Several equities research analysts have issued reports on the company. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Friday, June 12th. Roth Mkm assumed coverage on shares of Coya Therapeutics in a report on Friday, June 5th. They issued a “buy” rating and a $12.00 price objective on the stock. Wall Street Zen lowered shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Monday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday, March 23rd.

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Jane Street Group LLC increased its stake in shares of Coya Therapeutics by 101.7% during the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after purchasing an additional 13,176 shares during the period. Prosperity Wealth Management Inc. boosted its stake in Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares during the period. Cetera Investment Advisers bought a new stake in Coya Therapeutics in the 4th quarter valued at $128,000. Occudo Quantitative Strategies LP acquired a new position in Coya Therapeutics in the 4th quarter valued at $66,000. Finally, CIBC Private Wealth Group LLC acquired a new position in Coya Therapeutics in the 4th quarter valued at $47,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Stock Down 3.2%

NASDAQ:COYA opened at $5.66 on Thursday. Coya Therapeutics has a 12-month low of $3.71 and a 12-month high of $7.75. The firm has a market capitalization of $132.78 million, a price-to-earnings ratio of -4.92 and a beta of 0.50. The stock’s 50 day moving average price is $4.75 and its two-hundred day moving average price is $4.76.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. Equities research analysts expect that Coya Therapeutics will post -1.49 EPS for the current year.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.